Suppr超能文献

血管加压素和特利加压素用于成人血管扩张性休克:九项随机对照试验的系统评价和荟萃分析

Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials.

作者信息

Serpa Neto Ary, Nassar Antônio P, Cardoso Sérgio O, Manetta José A, Pereira Victor G M, Espósito Daniel C, Damasceno Maria C T, Russell James A

出版信息

Crit Care. 2012 Aug 14;16(4):R154. doi: 10.1186/cc11469.

Abstract

INTRODUCTION

Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its analog terlipressin compared with catecholamine infusion alone in vasodilatory shock.

METHODS

A systematic review and meta-analysis of publications between 1966 and 2011 was performed. The Medline and CENTRAL databases were searched for studies on vasopressin and terlipressin in critically ill patients. The meta-analysis was limited to randomized controlled trials evaluating the use of vasopressin and/or terlipressin compared with catecholamine in adult patients with vasodilatory shock. The assessed outcomes were: overall survival, changes in the hemodynamic and biochemical variables, a decrease of catecholamine requirements, and adverse events.

RESULTS

Nine trials covering 998 participants were included. A meta-analysis using a fixed-effect model showed a reduction in norepinephrine requirement among patients receiving terlipressin or vasopressin infusion compared with control (standardized mean difference, -1.58 (95% confidence interval, -1.73 to -1.44); P < 0.0001). Overall, vasopressin and terlipressin, as compared with norepinephrine, reduced mortality (relative risk (RR), 0.87 (0.77 to 0.99); P = 0.04). Vasopressin compared with norepinephrine decreased mortality in adult patients (RR, 0.87 (0.76 to 1.00); P = 0.05) and in patients with septic shock (42.5% vs. 49.2%, respectively; RR, 0.87 (0.75 to 1.00); P = 0.05; number needed to treat, 1 to 15). There was no difference in adverse events between the vasopressin and control groups (RR, 0.98 (0.65 to 1.47); P = 0.92).

CONCLUSIONS

Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates weaning of catecholamines. In patients with septic shock, use of vasopressin compared with norepinephrine may also decrease mortality.

摘要

引言

儿茶酚胺是血管舒张性休克中最常用的血管加压药。然而,肾上腺素能低敏反应的发展以及随后儿茶酚胺加压活性的丧失使得有必要寻找其他选择。我们的目的是评估血管加压素及其类似物特利加压素与单独输注儿茶酚胺相比在血管舒张性休克中的效果。

方法

对1966年至2011年间发表的文献进行系统评价和荟萃分析。检索了Medline和CENTRAL数据库中关于危重症患者使用血管加压素和特利加压素的研究。荟萃分析仅限于评估血管加压素和/或特利加压素与儿茶酚胺在成年血管舒张性休克患者中使用情况的随机对照试验。评估的结果包括:总体生存率、血流动力学和生化变量的变化、儿茶酚胺需求量的减少以及不良事件。

结果

纳入了9项试验,共998名参与者。采用固定效应模型的荟萃分析表明,与对照组相比,接受特利加压素或血管加压素输注的患者去甲肾上腺素需求量减少(标准化均数差,-1.58(95%置信区间,-1.73至-1.44);P<0.0001)。总体而言,与去甲肾上腺素相比,血管加压素和特利加压素降低了死亡率(相对危险度(RR),0.87(0.77至0.99);P = 0.04)。与去甲肾上腺素相比,血管加压素降低了成年患者的死亡率(RR,0.87(0.76至1.00);P = 0.05)以及感染性休克患者的死亡率(分别为42.5%对49.2%;RR,0.87(0.75至1.00);P = 0.05;需治疗人数,1至15)。血管加压素组和对照组之间不良事件无差异(RR,0.98(0.65至1.47);P = 0.92)。

结论

血管加压素用于血管舒张性休克是安全的,与死亡率降低相关,并有助于儿茶酚胺的撤机。在感染性休克患者中,与去甲肾上腺素相比,使用血管加压素也可能降低死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ea4/3580743/1febeb98c729/cc11469-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验